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Abstract Objective: To construct
a reliable and clinically practical
instrument for monitoring opioids and
benzodiazepine withdrawal symp-
toms in pediatric ICU patients.
Design: Instrument development.
Setting: Intensive care unit in an
academic children’s hospital. Patients
and participants: 79 patients up to
age 16 years on intravenous midazo-
lam and/or opioids for C5 days. An
expert panel of 85 physicians and
nurses rated clinical relevance of
withdrawal symptoms. Interven-
tion: During drug weaning repeated
observations were performed with a
checklist of 24 withdrawal symptoms
described in the literature. Measure-
ments and results: For 76 children,
932 observations were obtained within
24 h after decrease and/or discontinu-
ation of midazolam or opioids. Most
frequent symptoms were tachypnea,
agitation, motor disturbance, diarrhea,
fever, anxiety, sleep disturbance and
hypertension (14.6–29.6%). Multidi-
mensional scaling (MDS) was
performed to detect the underlying
empirical structure of co-occurrences
of symptoms. An expert panel judged
clinical relevance of each withdrawal
symptom on a four-point scale ranging
from ‘definitively so’ to ‘definitively
not’. Agitation, anxiety, inconsolable
crying, increased muscle tension,
tremors, tachycardia and sweating
were considered relevant by 85–95%
of the experts. On the basis of the MDS
results and the experts’ opinions, 15
symptoms were included in the final
instrument. Conclusions: We are the
first to develop an assessment tool for
withdrawal symptoms in pediatric ICU
patients on the basis of the underlying
empirical structure of co-occurrences
of withdrawal symptoms that experts
considered relevant. Future studies
need to define cut-off points and clarify
psychometric issues.
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Introduction
Many critically ill children admitted to a specialized intensive
care unit (ICU) receive benzodiazepines and/or opioids to
reduce pain and anxiety. Long-term exposure to these medi-
cations may result in physical dependency. These patients are
at risk for withdrawal symptoms after abrupt discontinuation
or too rapid tapering-off of these medications [1].
Signs and symptoms of withdrawal can be categorized
into three main groups: overstimulation of the central
nervous system (CNS), gastrointestinal dysfunction, and
autonomic dysregulation [1–3].
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A reliable, validated and clinical useful assessment tool
is indispensable for monitoring withdrawal syndrome.
Two such tools are available, the Sedation Withdrawal
Score (SWS) and the Opioid Benzodiazepine Withdrawal
Scale (OBWS) [4, 5]. Yet each has its limitations. The
SWS includes 12 symptoms. While all these symptoms
seem clinically relevant for assessing withdrawal, data on
validity and reliability are lacking. The OBWS included
16 symptoms and signs of withdrawal and was evaluated
in a small sample of PICU children (n = 15) comparing
OBWS scores and nurses’ clinical judgment. Sensitivity of
the OBWS at scores 8 (cut-off) or higher was 50% and the
specificity was 87%, which implies moderate validity of
the scale [5]. Symptoms of the OBWS were indirectly
adapted from the Neonatal Abstinence Score [6].
Recently, Franck and colleagues tested the OBWS in
83 pediatric ICU patients and provided a preliminary
validity and reliability evaluation of an 11-item reduced
version which they named the Withdrawal Assessment
Tool-1 (WAT-1) [7]. WAT-1 observation includes four
steps. The first is retrieval of information on loose stools,
vomiting and temperature of the previous 12 h. The sec-
ond is a 2-min pre-stimulus observation on state, tremor,
sweating, uncoordinated movement and yawning/sneez-
ing. The third is a 1-min stimulus observation on startle to
touch and muscle tone. The fourth is maximally a 5-min
post-stimulus observation to determine time to gain calm
state. In all, the WAT-1 includes four CNS symptoms,
two autonomic dysregulation symptoms, two symptoms
of gastrointestinal dysfunction and three items derived
from the State Behavioral Scale [8]. WAT-1 scores of 3
or higher (on a scale of 0–12) revealed the best sensitivity
and specificity (87 and 88%, respectively) in relation to
NRS-withdrawal ratings.
Within our line of research we studied the
(co-)occurrences of withdrawal symptoms in critically ill
children with the ultimate objective of identifying which
signs and symptoms are essential for developing a valid
and reliable assessment tool.
Materials and methods
Methods
Several steps of scale development were needed to con-
struct the Sophia Observation withdrawal Symptoms-
scale (SOS). The institutional review board approved the
study; because of the strictly observational and non-
invasive nature of this study, they waived the need for
informed consent.
The first step was a review of the literature on with-
drawal symptoms in critically ill children admitted to a
PICU based on an extensive evaluation of the literature
as recently published by our group [3]. Based on this
review, we selected 24 signs and symptoms for inclusion
in a preliminary scale, which we called the Sophia Ben-
zodiazepine and Opioid Withdrawal Checklist (SBOWC).
Twelve signs and symptoms concerned the central ner-
vous system, four the gastrointestinal tract, and eight the
autonomic nervous system (see Table 1).
The second step was a prospective observational study in
critically ill children admitted to the ICU of the Erasmus
MC—Sophia Children’s Hospital between September 2005
and February 2006. Eligible for inclusion were children aged
B16 years who had received midazolam (benzodiazepine),
morphine or fentanyl (opioids) by continuous infusion for
at least 5 days.
The SBOWC was assessed within 24 h after tapering-
off or cessation of midazolam and/or opioids (morphine
or fentanyl). All nurses had received verbal and written
instruction on the application of the SBOWC. An instruc-
tion manual explaining the signs and symptoms to be
observed was available at each patient’s bedside. Nurses’
interobserver reliability (Cohen’s kappa) for the individual
items of the SBOWC ranged from 0.59 to 1.0. The intra-
class correlation coefficient was 0.85 (95% CI 0.69–0.94).
The face validity was supported by the judgement of ten
experienced pediatric intensive care physicians. Further-
more, the construct validity of the SBOWC was promising
as shown by a Spearman rank correlation coefficient (rs) of
0.51 between total doses of midazolam and maximum
Table 1 Percentages of occurrences of withdrawal symptoms for
the weaning group (WEAN) and the unsuccessful weaning group
(WEAN-)
Withdrawal symptoms WEAN (n = 932) WEAN- (n = 94)
76 patients 27 patients
Agitation 21.1 46.2
Anxiety 14.8 24.7
Muscle tone 13.0 28.0
Motor 19.8 37.6
Tremors 2.8 3.3
Crying 7.3 10.8
High pitched crying 3.6 4.3
Grimacing 10.1 19.4
Sleeping 14.6 21.5
Seizures 0.3 0.0
Pupil dilation 1.2 2.2
Hallucination 1.1 1.1
Vomiting 4.5 11.8
Diarrhea 17.8 21.5
Feeding retention 12.4 25.5
Poor feeding 1.6 0.0
Tachycardia 9.3 16.1
Tachypnea 29.6 31.2
Hypertension 14.6 13.6
Fever 17.6 24.7
Sweating 12.9 22.6
Sneezing 1.0 1.1
Yawning 1.9 4.3
Mottling 9.2 15.1
n number of observations
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SBOWC sum score in 76 children (95% CI 0.32–0.66,
p \ 0.001). In addition the rs between total doses of opioids
and the maximum SBOWC sum score was 0.39 (95% CI
0.17–0.57, p \ 0.01, n = 71). The correlation between
duration of medication and maximum SBOWC sum score
was 0.52 (95% CI 0.34–0.67, p \ 0.001, n = 76) [9].
The third step was twofold. In step 3a the underlying
structure was identified by multidimensional scaling. Step
3b was to obtain expert opinion on the relevance of each of
the SBOWC symptoms. To this end we mailed a ques-
tionnaire to all pediatric intensive care physicians and
clinical fellows in pediatric intensive care of all eight PI-
CUs in the Netherlands and to critical care nurses of our
own PICU. In the first main question they were asked to
rate the relevance of each withdrawal symptom in criti-
cally ill children using a four-point scale ranging from
‘definitively yes’ to ‘definitively no’. In the second ques-
tion, they were asked to state which signs and symptoms
were definitely necessary for an assessment tool. Fur-
thermore, they were asked to provide demographic
aspects: discipline, age and years of work experience.
Step 4 selected the relevant items; signs and symptoms
which had insufficient discriminative value were eliminated.
Study population
Children aged B16 years admitted to the ICU of our level
three children’s hospital between September 2005 and
February 2006 were eligible for this study if they received
midazolam (a benzodiazepine), morphine or fentanyl (opi-
oids) by continuous infusion for at least 5 days. Exclusion
criteria were: status epilepticus treated with midazolam, use
of neuromuscular blocking agents (NMBA), and severely
disturbed behavior pattern on account of underlying neuro-
logical disease.
The observations were stratified into two groups. First, a
‘weaning group’ (WEAN), 932 observations in 76 children
obtained within 24 h after decrease and/or discontinuation of
midazolam and/or opioids. Those children were thought to
be at risk for developing withdrawal symptoms. Second, an
‘unsuccessful weaning’ group (WEAN-), 93 observations
in 27 children obtained before increasing midazolam and/or
opioids during the weaning process in order to counteract
possible withdrawal related signs and symptoms. We
expected that the WEAN- group would show more with-
drawal related signs and symptoms as compared to the
WEAN group.
Statistical analyses
As the frequency distribution of the symptoms of
SBOWC was highly skewed, the response categories were
dichotomized. Of clinical interest is determination of
the interrelationship of the signs and symptoms.
Conventionally, a correlation technique is used as mea-
sure of association. In this study it would not be of interest
to estimate associations between symptoms, however, but
rather to estimate the co-occurrences of these symptoms.
To that end, Jaccard’s measure of similarity tailored to
estimate these co-occurrences was applied.
Expert opinions
Each symptom of the checklist was recoded. A symptom
was coded relevant if the expert scored the first question
as ‘that’s definitely so’ or ‘that’s true’, or the second
question with ‘definitely necessary’. A symptom was
deemed relevant if 50% or more of the respondents
agreed on its relevance.
Multidimensional scaling
The goal of multidimensional scaling (MDS) analysis
technique in this study was to detect meaningful dimen-
sions of observed similarities and dissimilarities
(distances) between the withdrawal symptoms. The
(dis)similarities between the withdrawal symptoms iden-
tified by MDS were based on the co-occurrences of these
signs and symptoms. Then, MDS attempted to arrange
‘objects’ (withdrawal symptoms) in a space of a given
number of dimensions that does not entail substantial loss
of information. Nevertheless, in general, the more
dimensions we used in order to reproduce the matrix of
dissimilarities, the better the fit of the reproduced matrix
to the observed matrix. We considered the Jaccard mea-
sure as a similarity measure of co-occurrences. The
performances of the models were represented by the
normalized raw stress, a measure of model adequacy. This
coefficient varies from 0 to 1 and should be \0.05 as a
good fit. The Tucker’s u coefficient of congruence is a
measure of correspondence between the distances of the
empirical data and the distance derived from the model.
Ideally, this coefficient should be[0.95. Identification of
the clinical-empirical structure was by means of the
computer algorithm PROXSCAL (Proximity Scaling).
The symptoms hypertension and high pitched crying
were excluded from analysis. First, it was not always
possible to measure arterial blood pressure, e.g., in the
absence of an indwelling arterial catheter, in 386/932
(41%) observations. Second, high pitched crying could be
observed only in the absence of an endotracheal tube,
which was not always the case (629/932, 67%). Further-
more, as the SBOWC asked for observation of either
feeding retention or poor feeding, these items were taken
together in the MDS procedure.
Final item selection was based on the experts’ opinions
and the results of MDS. Inclusion in the SOS required signs
and symptoms to have a substantial score (z score) C0.30 on
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at least one dimension of the MDS solution. As a further
requirement, a symptom was deemed relevant if 50% or
more of the respondents agreed on its relevance.
The robustness of the MDS solution was tested with
tenfold cross-validation and presented by the mean (SD)
value.
Interobserver reliability was tested for dichotomous
items by Cohen’s kappa and the intraclass correlation
coefficient (ICC) for continuous data [10]. A Cohen’s
kappa below 0.65 was considered unsatisfactory [11].
Statistical analyses were performed with the Statistical
Package for Social Sciences (SPSS), version 14.0.
Results
Characteristics study sample
Seventy-nine children (57% boys) met the inclusion criteria.
Their median age was 3.4 months (range 0 days to
15.5 years). All 79 received midazolam at a median dose of
176 mcg/(kg h). Seventy-three children (92%) also received
opioids at a median dose of 14 mcg/(kg h). Midazolam was
administered for a median of 10 days (3–108 days); opioids
were administered for a median of 8 days (1–41 days). The
median (range) total dose of midazolam was 33 mg/kg (2–
595 mg/kg), and that of opioids 4 mg/kg (0–682 mg/kg).
For 76 children, 932 observations were obtained
within 24 h after decreasing and/or discontinuation of
midazolam and/or opioids (WEAN group). Three patients
were discharged before midazolam and/or opioids were
decreased or discontinued. Ninety-four ‘unsuccessful
weaning’ observations were obtained for 27 children in
the ‘unsuccessful weaning’ group (WEAN-). The latter
observations were obtained before midazolam and/or
opioids were increased during the weaning process in
order to counteract possible withdrawal related signs and
symptoms.
Interobserver reliability
Twenty-three observations were scored simultaneously by
the attending nurse and the principal investigator (EI).
The intraclass correlation coefficient was 0.97 (95% CI
0.92–0.98). The interobserver reliability (Cohen’s kappa)
for the individual items of the SOS ranged from 0.73
to 1.0.
Bivariate analysis of co-occurrences of withdrawal
symptoms
Table 1 presents occurrences of signs and symptoms for
the two conditions, i.e., observations performed within
24 h after weaning (WEAN, n = 932) of opioids/benzo-
diazepine and observations performed before decreasing
medication (WEAN-, n = 94). In addition, Table 2
shows the co-occurrences of signs and symptoms for the
WEAN group (lower triangle) and WEAN- group (upper
triangle).
For the WEAN group, the symptoms most frequently
observed were: tachypnea (29.6%), agitation (21.1%),
diarrhea (17.8%), fever (17.6%) anxiety (14.8%), sleep
pattern (14.6%) and hypertension (14.6%). For the
WEAN- group, agitation (46.2%), motor disturbance
(37.6%), tachypnea (31.2%), increased muscle tension
(28.0%) and feeding retention (25.5%) were observed
most frequently. The signs and symptoms tremors, hal-
lucination, seizure, pupil dilatation, sneezing and yawning
demonstrated very low prevalences (from 0.3 to 1.9).
With regard to co-occurrences (Table 2) the highest
percentage was seen for agitation co-occurring with motor
disturbance, both in the WEAN (9.5%) and WEAN-
(25.8%) groups. Groups substantially differed in frequencies
of the following co-occurrences: agitation/anxiety, agitation/
muscle tone, agitation/motor disturbance, agitation/grimac-
ing, agitation/sleeping, agitation/sweating, muscle tone/
motor disturbance. Co-occurrence rates with signs and
symptoms such as seizures, pupil dilatation, hallucinations,
yawning and sneezing were very low.
Experts’ opinions
In total, 85 experts—22 physicians and 63 nurses—
completed the questionnaire. Most of them (84.7%) were
female. The median work experience was 8 years for
physicians (IQR 4–11.3) and nurses (IQR 4.5–15) alike.
The following symptoms were considered most rele-
vant: agitation, anxiety, inconsolable crying, increased
muscle tension, tremors, tachycardia and sweating (84.7–
95.3%) (see Table 3). For five signs and symptoms fewer
than 50% of the experts agreed on relevance: seizures,
feeding retention, yawning, sneezing and mottling.
Multidimensional analysis of co-occurrences
The PROXSCAL-procedure with random starts was
chosen as the initial configuration. Twenty-one signs and
symptoms were entered and the solution of the MDS
procedure turned out to be three-dimensional. The nor-
malized raw stress was 0.0498, indicating a good fit. The
Tucker’s u coefficient of congruence equaled 0.97.
Decompositions of normalized Raw Stress ranged from
0.02 to 0.06. The tenfold cross-validation of the MDS
solution identified a mean normalized raw stress of
0.0501 (SD = 0.002) and a mean Tucker’s u coefficient
of congruence of 0.97 (SD = 0.0009). The conclusion is
justified that the solution identified is robust.
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The signs and symptoms seizures, pupil dilatation,
sneezing and yawning had a z score below 0.30 on either
of the three dimensions (see Table 4).
Finally, based on the MDS results as well as the
experts’ opinions, 15 signs and symptoms (Table 3)
were included in the SOS (see also Supplementary
materials).
Discussion
To our knowledge, this is the first study to identify the
underlying empirical structure of co-occurrences of
withdrawal symptoms that experts (physicians and nurses)
considered to be of relevance in critically ill children. The
co-occurrences of these signs and symptoms could be
adequately represented in a three-dimensional solution.
Nevertheless, the heterogeneity suggested that the signs
and symptoms did not constitute homogeneous clusters
within the three-dimensional solution. In all probabil-
ity, this should be attributed to the low levels of
occurrences of withdrawal symptoms, and, conse-
quently, to the low levels of co-occurrences. This finding
suggests that withdrawal symptoms vary between
individuals.
As withdrawal symptoms of children in the PICU are
usually treated immediately, extreme reactions are seen
only briefly. While ethically correct, because we put the
patients’ comfort first, this approach nevertheless makes it
difficult to determine co-occurrences of withdrawal
symptoms.
Although the underlying empirical structure of the
signs and symptoms was unraveled nicely, the question
arises whether the composed SOS based on MDS and the
experts’ opinions adequately covers all phenomena of the
withdrawal syndrome. Still, the signs and symptoms
included in the SOS have been extensively described in
the literature [3–5, 12]. Also, the tenfold cross validation
on children showed that the empirical solution was robust.
Table 2 Co-occurrences of withdrawal symptoms (%) in the weaning (WEAN) and unsuccessful weaning (WEAN-) groups
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Therefore, we conclude that the SOS truly covers the
withdrawal symptoms.
Several items were excluded from MDS analysis. We do
not preclude that assessment of arterial blood pressure
(ABP) might be of additional value, particularly in children
being ventilated for a long time. This item was excluded
because not all children had an indwelling arterial catheter.
High pitched crying can be assessed only when children are
not ventilated. This item was excluded, therefore, even
though experts identified it as relevant.
The item feeding, which consisted of subitems feed-
ing retention and poor feeding, was eliminated at a later
stage. Feeding retention was rated in children fed by
feeding tube, poor feeding in orally fed children. Feeding
retention may be the result of various causes and there-
fore this subitem is not sensitive enough. Poor feeding is
reported in the literature as a withdrawal symptom. Poor
feeding was judged relevant by 55% of the experts, but
feeding retention was judged irrelevant. Both subitems
were combined in the MDS analysis and it was impos-
sible to distinguish which feeding item had a substantial z
score. Also, taking into consideration that only very few
children (7/76, 9%) of the target group were orally fed for
1–2 days during ICU stay, we decided to eliminate the
combined item.
Table 3 Construction
of the SOS based on
two methods (MDS
and expert opinion)
SBOWC SBOWC–MDS SBOWC–expert opinion SOS
%
Anxiety 4 4 95.3 4
Agitation 4 4 84.7 4
Increased muscle tension 4 4 85.9 4
Motor disturbance 4
Slight muscle jerks 4 72.9 4
Uncoordinated, robust movements 4 78.8
Tremors 4 4 92.9 4
Inconsolable crying 4 4 88.2 4
High pitched crying * 4 68.2 9
Grimacing 4 4 76.5 4
Sleep disturbance
\1 h 4 4 71.8 4
Seizures 9 9 35.3 9
Pupil dilation 9 4 56.6 9
Hallucinations 4 4 76.5 4
Vomiting 4 4 61.2 4
Diarrhea 4 4 50.6 4
Feeding 4
Poor feeding 4 55.3 9
Feeding retention 9 43.5
Tachycardia 4 4 89.4 4
Tachypnea 4 4 69.4 4
Hypertension * 4 67.4 9
Fever 4 4 50.6 4
Sweating 4 4 90.6 4
Sneezing 9 9 24.7 9
Yawning 9 9 44.7 9
Mottling 4 9 45.9 9
*Not performed in the MDS analysis because of many missing observations, 4 meet criteria for inclusion,
9 do not meet inclusion criteria, SBOWC Sophia benzodiazepine and opioid withdrawal checklist
Table 4 Multidimensional scaling, dimensional quantifications (z
scores)
Withdrawal symptoms Dimension
1 2 3
Agitation 0.909 0.274 -0.190
Anxiety 20.594 20.591 0.223
Increased muscle tension 20.609 0.696 0.173
Motor disturbance 20.820 0.032 -0.280
Tremors 0.126 0.350 20.417
Crying -0.090 0.168 0.678
Grimacing 0.232 -0.006 20.668
Sleep disturbance (less than 1 h) 0.465 20.605 -0.177
Pupil dilation 0.153 -0.052 -0.236
Seizures 0.102 -0.200 0.070
Hallucinations -0.144 0.167 0.326
Vomiting 0.014 0.523 -0.259
Diarrhea -0.050 20.520 0.456
Feeding 0.523 20.391 0.340
Tachycardia 20.437 -0.108 0.227
Tachypnea 0.064 0.719 0.273
Fever 0.632 0.198 0.296
Sweating 20.360 -0.178 20.646
Yawning -0.174 0.121 -0.259
Sneezing 0.168 0.003 0.289
Mottling -0.110 20.600 -0.218
Z scores [0.30 were highlighted, these symptoms has substantial
score on one of the three dimensions
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The OBWS, SWS and WAT-1 overlap with our SOS
scale, except for the signs and symptoms hyperactive
Moro-reflex, high pitched crying, sneezing, yawning, fre-
quent suction required, seizures and pupil dilation [4, 5, 7].
These signs and symptoms were not included in the SOS.
Given the inherent age restriction for the Moro-reflex this
item cannot be included in a scale for all ages. We included
three other signs and symptoms—anxiety, grimacing and
tachycardia—which the three other scales do not contain.
On the basis of the literature, however, these signs and
symptoms were identified as withdrawal symptoms [3, 13].
We believe the SOS is more sensitive for assessing signs
and symptoms of benzodiazepine withdrawal than is the
WAT-1. Franck and colleagues report that validity analysis
suggested that the WAT-1 is better at detecting symptoms
of opioid rather than benzodiazepine withdrawal [7]. For a
PICU withdrawal scale this might be problematic given the
fact that benzodiazepine withdrawal symptoms are fre-
quent. The literature shows a broad spectrum of
benzodiazepine withdrawal symptoms [3]. Symptoms such
as agitation, anxiety, tremors, insomnia, fever, sweating,
and tachycardia have been described for both benzodiaze-
pine and opioid withdrawal. Symptoms such as movement
disorder, grimacing, inconsolable crying and hallucinations
have only been observed as benzodiazepine withdrawal.
The latter three symptoms were included in the SOS and not
in the WAT-1.
Franck and colleagues instead incorporated three
items of the State Behavioral Scale [7]. A methodological
underpinning of this approach is lacking, however.
The scales are nevertheless comparable with respect to
demographic characteristics of test study population and
psychometric properties. Validation is a never-ending
process and it would be worthwhile to compare both
assessment tools in a multicentre study with emphasis on
sensitivity to change.
Both scales could be easily integrated in daily practice
as a standard of care. However, the time to assess with-
drawal is 2 min for the SOS, in contrast with the WAT-1
which requires approximately 7 min observation. For
daily practice, the clinical utility of an assessment tool
increases if the observation time is brief.
A particular strength of the SOS is that it incorporates the
opinions of healthcare workers, so as to make it clinically
relevant. Also, it does not ask the raters to assess severity of
the symptoms, unlike the Sedation Withdrawal Score.
Therefore, we feel that it is not only easier to use, but also
more reliable, in that the reliability of an assessment tool will
increase as symptoms are unambiguous [14].
In future research, we will explore the sensitivity to
change of the SOS in critically ill children. Furthermore,
cut-off scores, sensitivity and specificity must be defined
for treatment purposes. In conclusion, the SOS is feasible
for assessing benzodiazepine and/or opioids withdrawal
symptoms in critically ill children in an ICU environment.
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